Antagonists of p38 MAPK as therapeutics for acute lymphoblastic leukemia.

p38 MAPK 拮抗剂作为急性淋巴细胞白血病的治疗剂。

• 批准号: nhmrc : 512431
• 负责人: A/Pr Linda Bendall
• 金额: $ 34.8万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/antagonists-p38-mapk-lymphoblastic-leukemia/88169
• 关键词: Antagonists; p38; MAPK; therapeutics; acute

New therapies are needed to treat patients with leukemia. Moving leukemic cells into the blood reduces their growth and increases the effects of chemotherapy. Currently we cannot move leukemic cells into the blood without moving normal blood forming cells, making them more sensitive to chemotherapy. We have identified a drug that only affects leukemic cell movement. This study will examine the potential of this drug to treat leukemia.

需要新的疗法来治疗白血病患者。将白血病细胞转移到血液中会减少其生长并增加化疗的效果。目前，我们无法在不移动正常造血细胞的情况下将白血病细胞转移到血液中，从而使它们对化疗更加敏感。我们已经确定了一种仅影响白血病细胞运动的药物。这项研究将检验这种药物治疗白血病的潜力。